Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice

John Foerster (Lead / Corresponding author), Kirsty Boswell, Jonathan West, Heather Cameron, Colin Fleming, Sally Ibbotson, Robert Dawe

Research output: Contribution to journalArticle

4 Citations (Scopus)
105 Downloads (Pure)

Abstract

Background: Narrowband NB-UVB phototherapy (NB-UVB) is an effective treatment for psoriasis, as demonstrated by clinical trials. However, due to required infrastructure and need for treatment attendance opinions on the value of offering this treatment in routine practice vary.
Aims: To provide high quality large-scale and long-term data on the efficacy of NB-UVB for psoriasis under real-world conditions in order to assist in management decisions. Methods: The following resources were employed: (1) complete and prospectively recorded prescription drug records for a population of 420,000 marked by low demographic mobility, (2) prospectively recorded clinical treatment outcomes for all NB-UVB treatment episodes occurring in the local population; (3) complete dermatology electronic treatment records of all psoriasis patients, allowing cross-validation of diagnoses and treatment records. Using these data sets, we analysed all first-ever initial NB-UVB treatment episodes occurring over 79 months (n = 1749) for both clinical outcomes and the effect of NB-UVB on the use of topical treatments for psoriasis.
Results: Around 75% of patients both achieved a status of “clear/minimal disease” and used fewer topical treatments. NB-UVB treatment led to a strong reduction for both steroid creams (25 %) and psoriasis-specific topicals, e.g. vitamin-D products (30%) during the 12-month period following NB-UVB treatment. The effects measured were specific as no effect of NB-UVB was noted on drug prescriptions unrelated to psoriasis. Results were independent of individuals administering and/or scoring treatment, as they were highly similar between four geographically separate locations.
Conclusions: NB-UVB treatment is highly effective and leads to a remarkable reduction in the need for topical cream treatments for a period of at least 12 months.
Original languageEnglish
Article numbere0181813
Pages (from-to)1-14
Number of pages14
JournalPLoS ONE
Volume12
Issue number8
DOIs
Publication statusPublished - 3 Aug 2017

Fingerprint

psoriasis
cream
Psoriasis
steroids
Steroids
Dermatology
Prescription Drugs
Vitamin D
Therapeutics
Pharmaceutical Preparations
drugs
vitamin D
infrastructure
electronics
clinical trials
demographic statistics
Drug Prescriptions
Phototherapy

Keywords

  • UVB
  • psoriasis
  • real-world data
  • clinical trial
  • efficacy

Cite this

@article{da90a46fef23473ba8ad84b361bcc709,
title = "Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice",
abstract = "Background: Narrowband NB-UVB phototherapy (NB-UVB) is an effective treatment for psoriasis, as demonstrated by clinical trials. However, due to required infrastructure and need for treatment attendance opinions on the value of offering this treatment in routine practice vary.Aims: To provide high quality large-scale and long-term data on the efficacy of NB-UVB for psoriasis under real-world conditions in order to assist in management decisions. Methods: The following resources were employed: (1) complete and prospectively recorded prescription drug records for a population of 420,000 marked by low demographic mobility, (2) prospectively recorded clinical treatment outcomes for all NB-UVB treatment episodes occurring in the local population; (3) complete dermatology electronic treatment records of all psoriasis patients, allowing cross-validation of diagnoses and treatment records. Using these data sets, we analysed all first-ever initial NB-UVB treatment episodes occurring over 79 months (n = 1749) for both clinical outcomes and the effect of NB-UVB on the use of topical treatments for psoriasis.Results: Around 75{\%} of patients both achieved a status of “clear/minimal disease” and used fewer topical treatments. NB-UVB treatment led to a strong reduction for both steroid creams (25 {\%}) and psoriasis-specific topicals, e.g. vitamin-D products (30{\%}) during the 12-month period following NB-UVB treatment. The effects measured were specific as no effect of NB-UVB was noted on drug prescriptions unrelated to psoriasis. Results were independent of individuals administering and/or scoring treatment, as they were highly similar between four geographically separate locations.Conclusions: NB-UVB treatment is highly effective and leads to a remarkable reduction in the need for topical cream treatments for a period of at least 12 months.",
keywords = "UVB, psoriasis, real-world data, clinical trial, efficacy",
author = "John Foerster and Kirsty Boswell and Jonathan West and Heather Cameron and Colin Fleming and Sally Ibbotson and Robert Dawe",
note = "No funding",
year = "2017",
month = "8",
day = "3",
doi = "10.1371/journal.pone.0181813",
language = "English",
volume = "12",
pages = "1--14",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice. / Foerster, John (Lead / Corresponding author); Boswell, Kirsty; West, Jonathan; Cameron, Heather; Fleming, Colin; Ibbotson, Sally; Dawe, Robert.

In: PLoS ONE, Vol. 12, No. 8, e0181813, 03.08.2017, p. 1-14.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice

AU - Foerster, John

AU - Boswell, Kirsty

AU - West, Jonathan

AU - Cameron, Heather

AU - Fleming, Colin

AU - Ibbotson, Sally

AU - Dawe, Robert

N1 - No funding

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Background: Narrowband NB-UVB phototherapy (NB-UVB) is an effective treatment for psoriasis, as demonstrated by clinical trials. However, due to required infrastructure and need for treatment attendance opinions on the value of offering this treatment in routine practice vary.Aims: To provide high quality large-scale and long-term data on the efficacy of NB-UVB for psoriasis under real-world conditions in order to assist in management decisions. Methods: The following resources were employed: (1) complete and prospectively recorded prescription drug records for a population of 420,000 marked by low demographic mobility, (2) prospectively recorded clinical treatment outcomes for all NB-UVB treatment episodes occurring in the local population; (3) complete dermatology electronic treatment records of all psoriasis patients, allowing cross-validation of diagnoses and treatment records. Using these data sets, we analysed all first-ever initial NB-UVB treatment episodes occurring over 79 months (n = 1749) for both clinical outcomes and the effect of NB-UVB on the use of topical treatments for psoriasis.Results: Around 75% of patients both achieved a status of “clear/minimal disease” and used fewer topical treatments. NB-UVB treatment led to a strong reduction for both steroid creams (25 %) and psoriasis-specific topicals, e.g. vitamin-D products (30%) during the 12-month period following NB-UVB treatment. The effects measured were specific as no effect of NB-UVB was noted on drug prescriptions unrelated to psoriasis. Results were independent of individuals administering and/or scoring treatment, as they were highly similar between four geographically separate locations.Conclusions: NB-UVB treatment is highly effective and leads to a remarkable reduction in the need for topical cream treatments for a period of at least 12 months.

AB - Background: Narrowband NB-UVB phototherapy (NB-UVB) is an effective treatment for psoriasis, as demonstrated by clinical trials. However, due to required infrastructure and need for treatment attendance opinions on the value of offering this treatment in routine practice vary.Aims: To provide high quality large-scale and long-term data on the efficacy of NB-UVB for psoriasis under real-world conditions in order to assist in management decisions. Methods: The following resources were employed: (1) complete and prospectively recorded prescription drug records for a population of 420,000 marked by low demographic mobility, (2) prospectively recorded clinical treatment outcomes for all NB-UVB treatment episodes occurring in the local population; (3) complete dermatology electronic treatment records of all psoriasis patients, allowing cross-validation of diagnoses and treatment records. Using these data sets, we analysed all first-ever initial NB-UVB treatment episodes occurring over 79 months (n = 1749) for both clinical outcomes and the effect of NB-UVB on the use of topical treatments for psoriasis.Results: Around 75% of patients both achieved a status of “clear/minimal disease” and used fewer topical treatments. NB-UVB treatment led to a strong reduction for both steroid creams (25 %) and psoriasis-specific topicals, e.g. vitamin-D products (30%) during the 12-month period following NB-UVB treatment. The effects measured were specific as no effect of NB-UVB was noted on drug prescriptions unrelated to psoriasis. Results were independent of individuals administering and/or scoring treatment, as they were highly similar between four geographically separate locations.Conclusions: NB-UVB treatment is highly effective and leads to a remarkable reduction in the need for topical cream treatments for a period of at least 12 months.

KW - UVB

KW - psoriasis

KW - real-world data

KW - clinical trial

KW - efficacy

U2 - 10.1371/journal.pone.0181813

DO - 10.1371/journal.pone.0181813

M3 - Article

VL - 12

SP - 1

EP - 14

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 8

M1 - e0181813

ER -